Search 

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

BCAL Diagnostics is a Sydney, Australia based blood diagnostics company with research facilities based in Kentucky, USA.

The BCAL lipid biomarker test is a universal blood test for the effective screening and monitoring of breast cancer.  The BCAL test is being developed to be safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BCAL Diagnostics is near completion of a 200-patient study. Initial results indicate the BCAL test has a greater than 90% sensitivity and specificity in the diagnosis of invasive ductal carcinoma which is 85% of all breast cancers. 

This will lead to a range of BCAL breast cancer blood tests that can be used across the full breast cancer disease management continuum. from pre-disposition to screening to long term monitoring.

BCAL Diagnostics is now seeking Series B capital of $5-$10M USD to support its global commercialisation activities.

Bionic Vision Technologies is the commercial entity which holds license to the patents around technology developed by Bionic Vision Australia.

Bionic Vision Australia brings together Australia’s leading experts in medical bionics to develop a bionic eye to restore vision to people with retinitis pigmentosa and age-related macular degeneration.  A prototype device has been successfully implanted into three patients for two years demonstrating outstanding safety and efficacy. 

Our capabilities which  differentiate us from competitors include:

1. Novel surgical techniques providing greater safety and stability od wide view devices

2. World leading, pioneering vision processing software

3. Unique arrangement and stimulation strategies of the electrodes

4. Unique diamond electrode encapsulation for the high acuity device

5. World leading psychophysics laboratory for assessing functionality of the devices

6. Unprecedented expertise and proven track record in preclinical studies

Our development portfolio consists of  wide view devices which aim to increase mobility and independence of patients and a high acuity device which will allow patients the ability to read large letters and recognise faces

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

We have developed the CloSys Hemostatic Device (HD)  - a highly differentiated technology for vascular closure after an interventional cardiology or peripheral procedure.  CloSys HD is unique in that it facilitates rapid closure but leaves NO foreign material behind in the patient.  It does this using a patented technology that eliminates heparin (anti-coagulant) from a small amount of the patient's blood and re-infuses this back to the puncture site and around the entire artery.  The de-heparinized blood rapidly and safely forms a clot to seal the artery naturally.  There are several other unique attributes of this product.  First  - it is the only product that will also seal "backsticks" or inadvertant punctures that go through the other side of the artery.  Backsticks are a leading cause of retroperitoneal hemorrhage.  Second - it preserves immediate re-access at the same site in the advent of an emergency.  

There is also an important economic value proposition offered by CloSys HD.  It will have a very low cost of goods so it could be sold for a price that will allow high margins to the manufacturer and cost savings to the hospital.  

We are approximately 25% of the way through a US pivotal trial and to date all performance and safety endpoints have been met.  There is a highly experienced management team and exceptional Board of Directors now associated with the company.    

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

Headquartered in the greater Iowa City area, Corvida Medical innovates intelligent technologies that are designed to represent the next generation of safe handling of hazardous drugs and excellence in design.  We address the problems inherent in current methods and develop smarter, simpler solutions to improve safety, productivity and quality for providers and patients. Our first technology, a novel new Closed System Transfer Device – the Halo™ — will be available in 2015.